← Evidence map

ArticleBiomedicines2026

Assessment of Blocking Interleukin-17 Antibodies in Tumor Immunotherapy with Checkpoint Inhibitors or Tumor-Specific T Cells in Implanted and UVB-Induced Cancers.

Yuko Tsuruta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Assessment of Blocking Interleukin-17 Antibodies in Tumor Immunotherapy with Checkpoint Inhibitors or Tumor-Specific T Cells in Implanted and UVB-Induced Cancers. | OpenQuestion